
Opinion|Videos|January 24, 2025
Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitor selection in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) depends on key factors including prior therapy response, BTK C481 mutation status, comorbidities, drug interaction profiles, dosing convenience, and adverse effect considerations, with noncovalent inhibitors offering particular benefit for those with BTK mutations or intolerance to covalent agents.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What key factors influence your decision when selecting among the available BTK inhibitors for patients with R/R CLL?
- What clinical or molecular features help identify patients with R/R CLL who are most likely to benefit from noncovalent BTK inhibitors compared with covalent BTK inhibitors?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Single-Tablet Bictegravir/Lenacapavir Effective After Treatment Switch
2
Chemoradiotherapy Improved Survival in Older Patients With Stage 2 NSCLC
3
Noninvasive Tests Show Promise for Tracking Treatment Response in Semaglutide MASH Trial
4
Flow Cytometry Tracks CAR T-Cell Therapy Persistence in Aggressive LBCL
5














































